Artal Group’s Relay Therapeutics RLAY Stock Holding History

Artal Group’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,213,725	Closed	-$15.2M	–	115
2023 Q2	$15.2M	Sell	1,213,725 -460,018	-27%	-$5.72M	0.47%	31
2023 Q1	$27.6M	Buy	1,673,743 +219,027	+15%	+$3.93M	1.64%	17
2022 Q4	$21.7M	Hold	1,454,716	–	–	1.21%	27
2022 Q3	$32.5M	Buy	1,454,716 +754,716	+108%	+$16.6M	1.39%	23
2022 Q2	$11.7M	Hold	700,000	–	–	0.63%	34
2022 Q1	$21M	Sell	700,000 -50,000	-7%	-$1.21M	0.88%	24
2021 Q4	$23M	Buy	750,000 +350,000	+88%	+$11.1M	0.63%	42
2021 Q3	$12.6M	Hold	400,000	–	–	0.28%	71
2021 Q2	$14.6M	Hold	400,000	–	–	0.3%	70
2021 Q1	$13.8M	Hold	400,000	–	–	0.24%	82
2020 Q4	$16.6M	Hold	400,000	–	–	0.36%	64
2020 Q3	$17M	Buy	+400,000	New	+$15.3M	0.41%	52

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Artal Group's RLAY Position: Q3 2023 in Review

Artal Group sold out of Relay Therapeutics (RLAY) in Q3 2023, closing a stake of 1,213,725 shares — an estimated $15.2M sold.

Artal Group first reported a position in RLAY in Q3 2020 and held it in 12 quarters. The position peaked at $32.5M in Q3 2022. 172 funds tracked by Wall St. Rank hold RLAY as of Q3 2023.

Artal Group reported no remaining Relay Therapeutics position as of Q3 2023 after selling out during the quarter.
Artal Group sold 1,213,725 Relay Therapeutics shares in Q3 2023, an estimated $15.2M.
Artal Group first reported a position in Relay Therapeutics in Q3 2020 and held it in 12 quarters.
Artal Group's Relay Therapeutics position peaked at $32.5M in Q3 2022.
172 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2023.

Based on Artal Group's 13F filing for Q3 2023, filed 13 Nov 2023.